SCHEMBL26099162

SCHEMBL26099162

Cc1nnn(-c2ccc(Cl)cc2)c1Cn1ncc(N(C)C)cc1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NOTUM Q6P988 1/20 0.36
PTGS2 P35354 1/20 0.35
GPBAR1 Q8TDU6 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
PFKFB3 Q16875 1/20 0.34
KCNH2 Q12809 1/20 0.33
CNR2 P34972 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
GRM1 Q13255 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24034796 0.85 L3MBTL1 (0.32) KMT2ACNR2L3MBTL1POLB
SCHEMBL24034822 0.79 HTR2B (0.42) MEN1KMT2ACYP1A2CYP3A4L3MBTL1
SCHEMBL24034810 0.77 SMN1; SMN2 (0.41) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL24034875 0.76 CCNC (0.37) MAPTMEN1KMT2ANOTUMNPC1
SCHEMBL24034828 0.70 GRIN2B (0.37) CNR2
SCHEMBL24034825 0.68 MAPT (0.38) MAPTKMT2ANOTUMPTGS2GPBAR1
SCHEMBL24098476 0.67 NOTUM (0.50) MAPTMEN1KMT2ANOTUMPTGS2
SCHEMBL21834180 0.67 NOTUM (0.62) MAPTMEN1KMT2ANOTUMPTGS2
SCHEMBL24034794 0.66 L3MBTL1 (0.45) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL30111766 0.66 DRD2 (0.34) KCNH2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4149933-B1 NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN LA ROCHE (CH) 2024-06-12 EP claimed
CN-115461337-A Novel triazolyl derivatives as GABA A alpha 5 PAM 豪夫迈·罗氏有限公司 2022-12-09 CN claimed
EP-4149933-B1 NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN LA ROCHE (CH) 2024-06-12 EP disclosed
US-20230135093-A1 TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-04 US disclosed
US-20230135093-A1 TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-04 US disclosed
US-20230135093-A1 TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN-LA ROCHE INC. (US) 2023-05-04 US disclosed
CN-115461337-A Novel triazolyl derivatives as GABA A alpha 5 PAM 豪夫迈·罗氏有限公司 2022-12-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135093-A1 TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM GABRA5, GABRA3, GABRB3 MAPT 1041/4885MEN1 1011/4885KMT2A 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.